Skip to content

The efficacy and safety of photodynamic diagnosis with SPP-005 at staging laparoscopy for advanced gastric cancer. Prospective multi-center trial.

The efficacy and safety of photodynamic diagnosis with SPP-005 at staging laparoscopy for advanced gastric cancer. Prospective multi-center trial. - GCPDD Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2091220309
Enrollment
105
Registered
2017-09-15
Start date
2017-09-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

large type 3 or type 4 gastric cancer

Interventions

Intervention type:DRUG Name of intervention:SPP-005(20 mg/kg) Dose form / Japanese Medical Device Nomenclature:GRANULES Route of administration / Site of application:ORAL Dose per administration:20 mg

Sponsors

Osaka University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Age older than 20 years 2)large type 3 whose size is over 8 cm or type 4 gastric cancer 3)ECOG Performance Status 0~1 4)Patients with any abnormal function in kidney, liver, blood, heart or lung. 5)Patients in treatment without other tumors. 6)Patient in well compliance with protocol and with written informed consent. 7)Patients who are able to visit the hospital according to the protocol schedule.

Exclusion criteria

Exclusion criteria: 1)Patient who is apparently diagnosed peritoneal dissemination by CT scan. 2)Patient having difficulty in oral ingestion 3)Patient with poor controlled infection 4)Patient with severe complications e.g. malignant hypertension, severe cardiac failure congestive, severe or unstable angina, myocardial infarction within last three months, cirrhosis in terminal stage, severe renal failure, diabetes mellitus poor control, severe pulmonary fibroses, active interstitial pneumonia, and so on. 5)Patients with current bone marrow transplantation 6)Patient with severe mental disorder 7)Patient with known allergy to 5-ALA or a similar compound 8)Participation in other clinical studies with investigational drugs concurrently 9)Patients during pregnancy/lactation period 10)Patient is not judged exclusive by investigator

Design outcomes

Primary

MeasureTime frame
The ratio of patients who were diagnosed peritoneal metastasis detected only by ALA photodynamic diagnosis

Secondary

MeasureTime frame
Incidence of Adverse event rate with each CTCAE grade Sensitivity , specificity, positive predictive value, negative predictive value

Countries

Japan

Contacts

Public ContactTsuyoshi Takahashi

Osaka University Hospital

ttakahashi2@gesurg.med.osaka-u.ac.jp+81-6-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026